Contineum MS drug stumbles in mid-stage trial
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
Winlevi is authorized in EU for the treatment of acne vulgaris
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
India presents one of the world’s largest untapped opportunities for neurovascular screening
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
Subscribe To Our Newsletter & Stay Updated